NPO Petrovax Pharm received a Russian Nanotechnology Product label, confirming Grippol Plus flu vaccine’s quality, effectiveness and safety. The label is given to companies that manufacture products with the use of Russian nanotechnology and that meet high quality, safety and environmental requirements

Petrovax Pharm is selling products as part of a joint partnership with LLC Vaga Pharm, a medication supplier on the Armenian market.

The Vladimir Potanin Foundation announced the results of the grant competition, which started in January 2014 in the framework of the Olympic Scholarships Program. The purpose of the program is to help future sports managers to get a quality professional education in the Russian International Olympic University (RIOU) in Sochi.

According to Orange Book, a regular report by Synergy Research Group, Petrovax Pharm has become one of the Top 5 companies by number of clinical trials started in Q2 2014 in the Russian pharmaceuticals market.

The immunobiological production unit of NPO Petrovax Pharm, a Russian pharmaceutical company, has produced more than 2.5 mln doses of Prevenar 13, a 13-valent conjugate pneumococcal vaccine, in easy to use disposable auto injectors. More than 5 mln doses are planned to be produced by the end of 2014.